Guayusa Ilex guayusa Loes.
Also called: guayusa tea, Ilex utilis (synonym)
Guayusa is a holly whose leaves have been brewed as a tea for centuries in the western Amazon, notably Ecuador. The leaves contain caffeine and theobromine plus chlorogenic acids and flavonoids; human studies are few, small and short.
- Category
- Botanical
- Part used
- Leaf
- Strongest evidence
- C Limited
- Native range
- Native to western South America to Venezuela (POWO: "W. South America to Venezuela")
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. This entry cites 3 RCTs of guayusa alone: single-dose randomized crossover trials of guayusa leaf extract versus placebo (two trials) or synthetic caffeine (one trial, 12 men) in healthy adults. [2]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBrain, mood and sleep2 topics
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Mood, energy and motor performance after a single dose | C | In a crossover RCT in 25 young adults, 600 mg leaf extract improved mood disturbance, fatigue and perceived energy versus placebo; 600 mg and 1,200 mg both raised blood pressure by 4-5 mmHg. [2] |
| Attention and working memory after a single dose | C | A placebo-controlled crossover RCT of a single 650 mg extract dose reported better N-Back and Serial 7s performance and higher focus ratings than placebo over 2 hours, but fewer correct No-go responses. [3] |
Main constituents: Methylxanthines caffeine and theobromine, chlorogenic acids, flavonoids and sugars [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Single doses of 600 mg and 1,200 mg leaf extract (acute crossover trial). [2]
- A single 650 mg dose of guayusa extract (acute crossover trial). [3]
- 200 mg of caffeine supplied by guayusa leaf extract, single dose (pharmacokinetic trial in 12 men). [4]
Upper limits
- Caffeine: FDA cites 400 milligrams a day as an amount not generally associated with negative effects for most adults; there is wide variation in how sensitive people are to caffeine and how fast they metabolize it. [6]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingFDA advises people who are pregnant, trying to become pregnant or breastfeeding to ask a health care provider whether they need to limit caffeine.
1 statement in the profile.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Guayusa is a caffeine source: in one trial, single extract doses raised systolic and diastolic blood pressure by 4-5 mmHg, and jitteriness increased with dose in women. [2]
- FDA estimates that toxic effects such as seizures can occur with rapid consumption of about 1,200 milligrams of caffeine. [6]
- In rats, a standardized guayusa concentrate given for 90 days produced effects comparable to an equivalent caffeine dose, with no added toxicity from other components; it was negative in Ames and chromosome aberration tests. [1]
- A 2020 review found broad guayusa consumption not associated with a history of adverse effects or product safety notifications, while noting that knowledge of its chemistry is still developing. [5]
Regulatory status
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [8]
- US: No NDI notification naming guayusa (Ilex guayusa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [9]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming guayusa (Ilex guayusa) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P5]
- Caffeine and theobromine content — Guayusa leaf contains the methylxanthines caffeine and theobromine (Kapp et al. 2016). [P1]
Supply and conservation
Absorption in people
- In a crossover trial in 12 men, 200 mg caffeine from guayusa leaf extract was bioequivalent to synthetic caffeine (Cmax and AUC ratios within 80-125%), with a smaller rise in epinephrine. [P8]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- FDA advises people who are pregnant, trying to become pregnant or breastfeeding to ask a health care provider whether they need to limit caffeine. [P9]
Sources for this profile
- Kapp RW Jr, et al. General and genetic toxicology of guayusa concentrate (Ilex guayusa). Int J Toxicol 2016;35(2):222-42 (PMID 26811391), 2016-03. pubmed.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
- GBIF species API: IUCN Red List category for Ilex guayusa, 2026-10-29. api.gbif.org
- Wise G, Negrin A. A critical review of the composition and history of safe use of guayusa: a stimulant and antioxidant novel food. Crit Rev Food Sci Nutr 2020;60(14):2393-2404 (PMID 31366209), 2020. pubmed.ncbi.nlm.nih.gov
- Krieger DR, et al. The safety, pharmacokinetics, and nervous system effects of two natural sources of caffeine in healthy adult males. Clin Transl Sci 2016;9(5):246-251 (PMID 27320048), 2016-10. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Spilling the Beans: How Much Caffeine Is Too Much? (content current as of 08/28/2024), 2024-08-28. fda.gov
Sources
- Kapp RW Jr, et al. General and genetic toxicology of guayusa concentrate (Ilex guayusa). Int J Toxicol 2016;35(2):222-42 (PMID 26811391), 2016-03. pubmed.ncbi.nlm.nih.gov
- Helwig NJ, et al. Acute, dose-response effects of guayusa leaf extract on mood, cognitive and motor-cognitive performance, and blood pressure, heart rate, and ventricular repolarization. J Int Soc Sports Nutr 2024;21(1):2379424 (PMID 39014963), 2024-12. pubmed.ncbi.nlm.nih.gov
- La Monica MB, et al. Acute effects of naturally occurring guayusa tea and Nordic lion's mane extracts on cognitive performance. Nutrients 2023;15(24):5018 (PMID 38140277), 2023-12-06. pubmed.ncbi.nlm.nih.gov
- Krieger DR, et al. The safety, pharmacokinetics, and nervous system effects of two natural sources of caffeine in healthy adult males. Clin Transl Sci 2016;9(5):246-251 (PMID 27320048), 2016-10. pubmed.ncbi.nlm.nih.gov
- Wise G, Negrin A. A critical review of the composition and history of safe use of guayusa: a stimulant and antioxidant novel food. Crit Rev Food Sci Nutr 2020;60(14):2393-2404 (PMID 31366209), 2020. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Spilling the Beans: How Much Caffeine Is Too Much? (content current as of 08/28/2024), 2024-08-28. fda.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew; WCVP data. Ilex guayusa Loes. (accessed 2026-10-29; Kew cannot warrant the accuracy of the data), 2026-10-29. powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.